New Stock News | Yifang Biological (688382.SH) Plans to List in Hong Kong, China Securities Regulatory Commission Requires Additional Explanation for Compliance with Production Safety.

The China Securities Regulatory Commission released the "Supplementary Materials Requirements for Overseas Issuance and Listing Record (February 2, 2026 - February 6, 2026)". The International Department of the China Securities Regulatory Commission issued supplementary material requirements for four companies, including asking Yifang Bio to provide clarification on the compliance operation of safety production and other related matters. According to the Hong Kong Stock Exchange disclosure on January 1st, Yifang Bio (688382.SH) submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC as its exclusive sponsor. The China Securities Regulatory Commission requested Yifang Bio to provide clarification on the following matters, and to have lawyers verify and provide clear legal opinions: 1. The business scope of the issuer's subsidiaries includes "design, production, agency, and publication of various types of advertisements." Please explain whether the business scope and actual business operations of the issuer and its subsidiaries involve sectors prohibited or restricted for foreign investment, and provide the basis for such judgments, as well as whether they continuously comply with foreign investment access policy requirements before and after this issuance and listing. 2. Whether the actual business of the issuer and its subsidiaries involves the development and application of human stem cells, genetic diagnosis and treatment technologies as specified in the "Special Management Measures for Foreign Investment Access (Negative List) " (2024 version), and provide clear basis. 3. In accordance with the requirements of the "Regulatory Rules Application Guide - Overseas Issuance and Listing No. 2", please explain the compliance operation of safety production and other aspects. The prospectus shows that Yifang Bio is a research-driven biopharmaceutical company based in China and globally, specializing in areas of significant unmet needs such as oncology, autoimmune diseases, and metabolic diseases. As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercial products (BPI-D0316 and D-1553), two core products in the clinical stage (D-2570 and D-0502), one clinical stage candidate product (D-0120), and three pre-clinical candidate products (YF087, YF550, and YF057).